Table 1 Clinical characteristics of patients in the training, internal validation, and external validation cohort
From: Tissue-resident microbiota signature in nasopharyngeal carcinoma
|  | Training cohort (n = 171) | Internal validation cohort (n = 172) | External validation cohort (n = 148) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | No of patients | Low risk (%) | High risk (%) | No of patients | Low risk (%) | High risk (%) | No of patients | Low risk (%) | High risk (%) |
Sex | |||||||||
 Female | 49 | 40 (28.8) | 9 (28.1) | 40 | 36 (24.2) | 4 (17.4) | 49 | 38 (36.5) | 11 (25.0) |
 Male | 122 | 99 (71.2) | 23 (71.9) | 132 | 113 (75.8) | 19 (82.6) | 99 | 66 (63.5) | 33 (75.0) |
Age/years | |||||||||
 < 45 | 91 | 76 (54.7) | 15 (46.9) | 93 | 86 (57.7) | 7 (30.4) | 48 | 38 (36.5) | 10 (22.7) |
 ≥ 45 | 80 | 63 (45.3) | 17 (53.1) | 79 | 63 (42.3) | 16 (69.6) | 100 | 66 (63.5) | 34 (77.3) |
T stage | |||||||||
 T1 | 17 | 16 (11.5) | 1 (3.1) | 16 | 13 (8.7) | 3 (13.1) | 4 | 2 (1.9) | 2 (4.6) |
 T2 | 32 | 27 (19.4) | 5 (15.6) | 31 | 26 (17.5) | 5 (21.7) | 32 | 25 (24.0) | 7 (15.9) |
 T3 | 88 | 71 (51.1) | 17 (53.1) | 94 | 86 (57.7) | 8 (34.8) | 69 | 48 (46.2) | 21 (47.7) |
 T4 | 34 | 25 (18.0) | 9 (28.1) | 31 | 24 (16.1) | 7 (30.4) | 43 | 29 (27.9) | 14 (31.8) |
N stage | |||||||||
 N0 | 18 | 17 (12.2) | 1 (3.1) | 26 | 24 (16.1) | 2 (8.7) | 10 | 6 (5.8) | 4 (9.1) |
 N1 | 83 | 71 (51.1) | 12 (37.5) | 71 | 64 (43.0) | 7 (30.4) | 59 | 45 (43.3) | 14 (31.8) |
 N2 | 52 | 36 (25.9) | 16 (50.0) | 42 | 36 (24.1) | 6 (26.1) | 58 | 41 (39.4) | 17 (38.6) |
 N3 | 18 | 15 (10.8) | 3 (9.4) | 33 | 25 (16.8) | 8 (34.8) | 21 | 12 (11.5) | 9 (20.5) |
TNM stage | |||||||||
 I | 7 | 6 (4.3) | 1 (3.1) | 6 | 6 (4.1) | 0 (0.0) | 0 | 0 (0) | 0 (0.0) |
 II | 26 | 25 (18.0) | 1 (3.1) | 19 | 17 (11.4) | 2 (8.7) | 13 | 11 (10.6) | 2 (4.6) |
 III | 90 | 71 (51.1) | 19 (59.4) | 87 | 79 (53.0) | 8 (34.8) | 75 | 54 (51.9) | 21 (47.7) |
 IV | 48 | 37 (26.6) | 11 (34.4) | 60 | 47 (31.5) | 13 (56.5) | 60 | 39 (37.5) | 21 (47.7) |
WHO pathological type | |||||||||
 Undifferentiated | 164 | 133 (95.7) | 31 (96.9) | 166 | 144 (96.6) | 22 (95.6) | 145 | 102 (98.1) | 43 (97.7) |
 Differentiated | 7 | 6 (4.3) | 1 (3.1) | 6 | 5 (3.4) | 1 (4.4) | 3 | 2 (1.9) | 1 (2.3) |
EBV DNA (copies/ml) | |||||||||
 < 2000 | 79 | 66 (47.5) | 13 (40.6) | 76 | 66 (44.3) | 10 (43.5) | NA | NA | NA |
 ≥ 2000 | 92 | 73 (52.5) | 19 (59.4) | 96 | 83 (55.7) | 13 (56.5) | NA | NA | NA |
Chemotherapy | |||||||||
 No | 12 | 11 (7.9) | 1 (3.1) | 20 | 18 (12.1) | 2 (8.7) | 10 | 9 (8.7) | 1 (2.3) |
 Yes | 159 | 128 (92.1) | 31 (96.9) | 152 | 131 (87.9) | 21 (91.3) | 138 | 95 (91.4) | 43 (97.7) |
Disease progression | |||||||||
 No | 124 | 107 (77.0) | 17 (53.1) | 125 | 116 (77.8) | 9 (39.1) | 83 | 66 (63.5) | 17 (38.6) |
 Yes | 47 | 32 (23.0) | 15 (46.9) | 47 | 33 (22.2) | 14 (60.9) | 65 | 38 (36.5) | 27 (61.4) |
Distant metastasis | |||||||||
 No | 147 | 125 (89.9) | 22 (68.7) | 135 | 124 (83.2) | 11 (47.8) | 113 | 86 (82.7) | 27 (61.4) |
 Yes | 24 | 14 (10.1) | 10 (31.3) | 37 | 25 (16.8) | 12 (52.2) | 35 | 18 (17.3) | 17 (38.6) |
Death | |||||||||
 No | 134 | 116 (83.4) | 18 (56.2) | 136 | 125 (83.9) | 11 (47.8) | 111 | 84 (80.8) | 27 (61.4) |
 Yes | 37 | 23 (16.6) | 14 (43.8) | 36 | 24 (16.1) | 12 (52.2) | 37 | 20 (19.2) | 17 (38.6) |